The drug is currently classified as a Schedule I controlled substance in the United States, leading those seeking treatment ...

MIAMI – The lack of progress in development of drugs to effectively treat posttraumatic stress disorder (PTSD) has become a "crisis" and has led to a significant shift in the US Department of Veterans ...

(Reuters) -The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's antipsychotic drug in combination with Viatris' antidepressant ...

New research published in the journal Neuroscience provides evidence that nitrous oxide may be an effective treatment for ...

The FDA has accepted an investigational new drug application from a global biotechnology company for its investigational, ...

An experimental drug reverses PTSD-like symptoms in mice. The corresponding study was published in Signal Transduction and Targeted Therapy and may pave the way for a new treatment for PTSD. “This ...

About 12 million adults in the United States are affected by PTSD, impacting between 4% and 8% of the adult population—and up to 30% of military personnel and veterans. Strikingly, 63% of veterans ...

CONTENT WARNING: This article references suicide. Please take caution when reading. If you need mental health support, call or text the national suicide and crisis lifeline — 988 — or consult our ...

The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

Neurova Labs began the way many veteran-founded health technologies do, with frustration, loss and a growing belief that the systems designed to help were not addressing the full scope of the problem.

In a 10-1 vote, the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee said Otsuka Pharmaceutical Co. Ltd.’s studies of its combination post-traumatic stress disorder (PTSD) treatment did not ...